Due to exacerbation of pre-existing CVD, direct myocardial toxicity, and hypertension, 5–10% of patients receiving VEGFi (vascular endothelial growth factor inhibitors) TKIs develop LVD [6, 74]. This evidence concerns the gene VEGFA and hypertensive disorder.